KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy

By afschroeder • December 18, 2025

Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N, Saji S, Miyoshi Y, Bardia A, Harbeck N, Haiderali A, Fan L, Mejia JA, Karantza V, Llombart-Cussac A. KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy. Clin Cancer Res. 2025 Dec 17. doi: 10.1158/1078-0432.CCR-25-1818. Epub ahead of print. PMID: 41405563.

Tags: Hematology/Oncology, Publications

Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia

Zuckerman JE, Larson S, Abdelnour L. Serine Protease HTRA1 Membranous Nephropathy With Polytypic IgG Concurrent With Plasma Cell Dyscrasia. Kidney Med. 2026 May 12;8(7):101402. doi:[...]

Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer

Mouabbi JA, Lipsyc-Sharf MD, Yan F. Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):1-16.[...]

Interpreting MRD results and integrating assays into practice

Lipsyc-Sharf MD. Interpreting MRD results and integrating assays into practice. Clin Adv Hematol Oncol. 2026 Jun;24(4 Suppl 4):7-11. PMID: 42283708.